Fatma Wise

Dr. Fatma Wise

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Journal of Affective Disorders
Verified
Journal Article
Closed access
TSTara Srivastava
Tara Srivastava
KLKeegan Lee
Keegan Lee
RERebecca Ehrenkranz
Rebecca Ehrenkranz
PCPhilip J. Cozzolino
Philip J. Cozzolino
FWFatma Wise
Fatma Wise
JPJennifer Kim Penberthy
Jennifer Kim Penberthy

13 April 2026 in Psychoactives
Verified
Journal Article
Open access
PDF file
JPJennifer Kim Penberthy
Jennifer Kim Penberthy
FWFatma Wise
Fatma Wise
NCNicholas Cherup
Nicholas Cherup
JPJennifer Morgan Penberthy
Jennifer Morgan Penberthy
EMEvaline Mitchell
Evaline Mitchell
JSJonathan Singer
Jonathan Singer
Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a psychedelic compound, in treating PGD in adults, with a focus on young adults. The study will involve 20 participants diagnosed with PGD. Each participant will undergo a structured therapeutic process that includes a preparatory session, a single 25 mg dose of psilocybin, and post-session integration. Throughout the study, participants will be monitored via symptom assessments, including qualitative and quantitative data, with the main aims related to safety, feasibility and acceptability. Functional MRIs will be obtained pre- and post-dosing and collected during a standardized grief-elicitation methodology. Key outcome measures include changes in the severity of PGD and trauma symptoms, cognitive flexibility, openness to experience, meaning in life and subjective experiences during the psilocybin session. Neural activity will also be evaluated through fMRI to better understand the neurobiological effects of the treatment. This research represents one of the first clinical protocols specifically focused on the potential of psilocybin for treating PGD. The goal is to assess feasibility and safety while laying the groundwork for future randomized controlled trials.